Skip to content

Effect of Liposomal Bupivacaine Thoracic Paravertebral Block on Postoperative Chronic Pain in Patients Undergoing Thoracoscopic Lung Cancer Surgery: A Single-Center, Prospective, Double-Blind, Randomized Controlled Clinical Trial

Effect of Liposomal Bupivacaine Thoracic Paravertebral Block on Postoperative Chronic Pain in Patients Undergoing Thoracoscopic Lung Cancer Surgery: A Single-Center, Prospective, Double-Blind, Randomized Controlled Clinical Trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500097040
Enrollment
Unknown
Registered
2025-02-11
Start date
2025-02-15
Completion date
Unknown
Last updated
2025-02-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic post-surgical pain

Interventions

Bupivacaine liposome group:Ultrasound-guided thoracic paravertebral nerve block will be performed before the operation. Diluted bupivacaine liposome 15 ml ( 133 mg ) was given at T3-4 and T5-6.
Ropivacaine group:Ultrasound-guided thoracic paravertebral nerve block will be performed before the beginning of the operation. 0.33 % ropivacaine 15 ml ( 50 mg ) was given at T3-4 and T5-6 levels.

Sponsors

Henan Provincial Chest Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 64 Years

Inclusion criteria

Inclusion criteria: Aged 18-64 years old ; preoperative or intraoperative pathological diagnosis of lung cancer requires thoracoscopic surgery ( lung wedge, lung segment, lung lobe ) ; american Society of Anesthesiologists ( ASA ) grade I-III ; patients or their legal representatives signed informed consent.

Exclusion criteria

Exclusion criteria: 1. Communication disorders, inability to cooperate with the investigator, such as language comprehension disorders, psychiatric disorders, epilepsy, history of Parkinson's disease or myasthenia gravis, etc. 2. Identifying/suspected to have a history of alcohol, analgesic drugs, or other substance abuse and addiction. 3. Those who are allergic to the drugs in this study. 4. Long-term chronic pain before surgery. 5. Previous history of thoracic surgery. 6. Refusal to participate in this study. 7. In the opinion of the doctor in charge or the investigator, there are other conditions that are not suitable for participating in this study (the reasons need to be recorded). 8. Patients participating in other clinical studies.

Design outcomes

Primary

MeasureTime frame
Incidence of postoperative chronic pain;The oxygenation index ( PaO 2 / FiO 2 ) was measured on the 1st and 3rd day after operation.;

Secondary

MeasureTime frame
Acute Pain Intensity Post-Surgery;Total Consumption of Opioids within 48 Hours after Surgery;Frequency and dose of non-steroidal anti-inflammatory drugs ( NSAIDs ).;The first ambulation time after operation;Postoperative Complication Rate;Patients' satisfaction;Hospitalization time;Serum markers;The incidence of chronic pain at 3 months after operation.;The incidence of chronic pain at 12 months after operation.;

Countries

China

Contacts

Public ContactJunhui Zhou

Henan Provincial Chest Hospital

zhoujunhui1985@126.com+86 371 6566 2765

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026